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Background: MicroRNA-7 (miR-7) has been observed as a potent tumour suppressor in multiple cancer types including breast
cancer. The aim of this study was to investigate the response sensitivities of metastatic breast cancer cells to miR-7 and the roles
of miR-7 in the interaction of endothelial cells and metastatic cancer cells.
Methods: Expression profile of miRNAs in a breast cancer specimen cohort and breast cancer cells were determined using real-
time quantitative miRNA assays. Effect of the altering expression of miR-7 on migration, invasion, proliferation, interaction and
underlying molecular mechanism of breast cancer cells and endothelial cells was investigated after treatment with the synthesised
mimic of miR-7. Luciferase activity analysis was performed to validate Wave-3 as a novel target of miR-7.
Results: miR-7 expression was negatively correlated with the stage, grade and survival of the breast cancer patients. There was
also differential expression of miRNAs including miR-7 in the breast cancer cells. The synthesised mimic of miR-7 inhibits the
motility and wound healing potential of breast cancer cells. The highly metastatic MDA-MB-231 cells are more sensitive to the
miR-7 treatment than the poorly invasive MCF-7 cells. Treatment with miR-7 downregulated the expression of EGFR, IGF1R and
Wave3 in MDA-MB-231 cells but not in MCF-7 cells. In addition, we further demonstrated that miR-7 inhibited the proliferation,
migration and invasion of endothelial cells. And more importantly, miR-7 suppressed the homing and migration of endothelial
cells to more aggressive tumour cell conditions.
Conclusions: Given the dual inhibitory effect of miR-7 on metastatic breast cancer cells alone and the interaction of endothelial
cells with the tumour-conditioned microenvironment, we suggest miR-7 may be a new therapeutic candidate for its capacity not
only to prevent breast cancer cell spreading but also to inhibit tumour-associated angiogenesis in the metastatic breast cancer.
Breast cancer is the most common cancer type among women and
the second most common cancer overall, with nearly 1.7 million
new cases diagnosed and over 0.5 million death every year
worldwide (Ferlay et al, 2015a). This accounts forB12% of all new
cancer cases and 25% of all cancers in women. The UK is among
the top 7 countries with the highest incidence of breast cancer
(Ferlay et al, 2015b). Breast cancer starts as a primary tumour, and
this progresses to metastasise to distance sites. The most common
sites of breast cancer metastasis are bone, liver, brain and distant
lymph nodes. Breast cancer is a heterogeneous disease, and can be
classified into multiple subtypes according to distinct histopatho-
logical features, genetic and genomic variability, and diverse
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prognostic outcomes (Curtis et al, 2012). Despite intensive
investigation, the cellular and molecular mechanisms of breast
cancer metastasis is still not clear. Due to the complexity of the
cancer onset and progression, it is still a clinical challenge for the
early diagnosis and efficient treatment of breast cancer metastasis,
which accounts for 90% of all breast cancer deaths. Very often the
metastatic breast cancer becomes incurable and the patients can be
only treated through a palliative care approach (Sledge et al, 2014).
Additional studies are needed to elucidate the molecular mechan-
isms and identify the histological characteristics which can be
useful for the identification of a pre-metastatic state.
MicroRNAs (miRNAs, miRs) are endogenous, non-coding
RNAs, which are 18–20 nucleotides and regulate gene expression
post-transcriptionally. They bind to the 30-untranslated region of
mRNAs thus blocking mRNA translation. They can also promote
mRNA instability and facilitate its degradation (Guo et al, 2010).
A single miRNA may target and exert full functional effects on
several hundred mRNAs over the entire human genome and show
multiple targets in a solid tumour such as breast cancer (Jansson
and Lund, 2012). miRNAs are master regulators of cell behaviour
under normal and pathological conditions. In metastatic tumours,
miRNAs can act as epigenetic regulators of gene expression which
control multiple aspects of metastasis (Tavazoie et al, 2008).
Regulation by miRNAs can be involved in the multiple stages
of dissemination of cancer cells from the primary tumour site
including intravasation and extravasation. It also plays a role in
tumour cell homing to distant sites, tumour–stroma cell interac-
tions, dormancy and outgrowth (Ell et al, 2013). As there are no
effective targeted therapeutic drugs to prevent or halt breast cancer
metastasis in the clinic, miRNAs may be a potential avenue for a
new therapeutic approach. This is supported by the recent studies
with miR-34, a master regulator of tumour suppression (Bader,
2012), which has shown promising results in animal models of
cancer and has become the first microRNA to enter multicentre
Phase 1 clinical study in solid tumours and haematological
malignancies (ClinicalTrials.gov Identifier: NCT01829971).
In this study we hypothesised that certain breast cancer cells
may have a distinctive sensitivity to a specific miRNA mimic which
regulates critical pathways involved in aggressive tumour cell
behaviours, including spreading and invasion. We first screened a
panel of miRNAs in a breast cancer cohort, and then determined
the differential expression of lead miRNAs in a panel of breast
cancer cell lines with varying invasion properties. We observed that
the highly metastatic MDA-MB-231 cells show the lowest
expression of miR-7 compared to the other breast cancer cells
considered. Furthermore, we used chemically synthesised mimics
of miRNAs, including miR-7, to evaluate whether they had an
inhibitory effect on motility and wound healing potential of breast
cancer cells. We then investigated how miR-7 mimic can modulate
the behaviours of breast cancer cells, and what were the possible
mechanisms by which metastatic cells are more susceptible to the
anti-tumoural effect to miR-7. Furthermore, in order to evaluate
the potential therapeutic application of miR-7 in the control of
tumour metastasis, we evaluated the effect of miR-7 on endothelial
cell behaviours including migration, proliferation, invasion and
tumour–endothelial interaction.
Our data indicate that miR-7 controls the angiogenic potential
of endothelial cells in the presence of aggressive tumour conditions
as well. To the best of our knowledge, this is the first report
describing the dual inhibitory effect of miR-7 on invasive breast
cancer cells and endothelial cells, which are both essential for
breast cancer metastasis. We therefore support a new concept
for the development of a miR-7 replacement therapy to prevent or
delay breast cancer metastasis.
MATERIALS AND METHODS
Human breast cancer samples. Breast cancer patient specimens
were acquired in accordance with institutional guidelines after
ethical approval by the Bro Taf Health Authority local ethics
committee. Written informed consent was obtained from all study
subjects. Primary breast cancer tissues (n¼ 127) and adjacent non-
cancerous mammary tissue (n¼ 33) were collected immediately
after surgical excision and stored at  80 1C until use. All tissues
were randomly numbered and the details were only made known
after all analyses were completed. The presence of tumour cells in
the collected samples was verified by an independent consultant
pathologist using haematoxylin and eosin stained frozen sections.
A routine follow-up was carried out after surgery and details were
stored in a customised database. The median follow-up period was
120 months. The clinical data are provided in Table 1.
Cells and cell culture. All human breast cell lines used for this
study were obtained from the ATCC (Rockville, MD, USA). The
human breast cancer cell lines MDA-MB-231, MDA-361, MCF-7,
ZR-75.1, BT-474, BT-20, T47D and BT-549 were routinely
maintained in Dulbecco’s modified Eagle’s medium/Ham’s F12
(Sigma-Aldrich, Irvine, UK) supplemented with 10% foetal calf
serum (FCS), and 1 penicillin and streptomycin. MCF10A cells
were maintained in MEGM (mammary epithelial growth medium)
(Lonza, Slough, UK) supplemented with 100 ngml 1 cholera
Table 1. Primers Used for the Real-Time qRT-PCRa
Gene Sense primer (50–30) Anti-sense primer (50–30)
ANGPT2 GTCCACATCAAACTCTAAGGA ACTGAACCTGACCGTACAATGTTAACGTGTAGATGCCA
CXCR4 GCCTCTTTTGCAGATATACAC ACTGAACCTGACCGTACAGGTGGGCAGGAAGATTTTAT
CXCR7 TTCCAAGACTTTTTCTGCCT ACTGAACCTGACCGTACATGCGCAAGCTATAAACAAAG
EGFR AGAGTCTCAAAGCCATGTT ACTGAACCTGACCGTACACCATCCTAAGCATGACTCC
ERK ACACGCAGTTGCAGTACA ACTGAACCTGACCGTACAGGGGCTGATCTTCTTGAT
GAPDH CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG
GROa TCTTCCGCTCCTCTCAC ACTGAACCTGACCGTACACGGACGCTCCTGCTG
IGF1R GTGTTCTTCTATGTCCAGGC ACTGAACCTGACCGTACAAGACGTACAGCATAATCACC
mTOR GCTGCAGAAGAAGGTCACT ACTGAACCTGACCGTACAAAGGAGATGGAACGGAAG
STAT3 CATGGAAGAATCCAACAACG ACTGAACCTGACCGTACAAATCAGGGAAGCATCACAAT
THBS1 ACCAACCGCATTCCAGAGTC ACTGAACCTGACCGTACATCAGGTTGGCATCCTCGAT
VEGFA GAGCCGGAGAGGGAG ACTGAACCTGACCGTACACTGGGACCACTTGGCAT
WAVE3 TGACACCATACAGAGATGAC ACTGAACCTGACCGTACACTGTTAGGGTTCAGCTTGTG
aThe z-sequence (which binds to the 30-end of the Amplifluor probes) are underlined.
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toxin. The human microvascular endothelial cells (HMVECs) (Life
Technologies, Paisley, UK) were maintained using Medium 131
supplemented with the addition of Microvascular Growth Supple-
ment (MVGS) in flasks treated with Attachment Factor Protein
(Life Technologies). All cells were incubated at 37 1C, with 5% CO2
and 95% humidity.
RNA isolation. Total cellular RNA was isolated from the cultured
breast cancer cells using TRI-Reagent RNA isolation agent (Sigma-
Aldrich) according to the manufacturer’s protocol. The quality and
concentration of RNA was determined through spectrophoto-
metric measurement (NanoPhotometer, IMPLEN, Munich,
Germany).
Real-time PCR-based miRNA detection. Expression of miRNAs
in the breast cancer cohort and breast cancer cell lines was
quantified using a Sybr-Green-based method described elsewhere
(Balcells et al, 2011). Alternatively, the Megaplex TaqMan
MicroRNA Arrays v2.0 and Megaplex Primer Pools following the
manufacturer’s instructions (Life Technologies) have also been
used. Expression of miRNAs in breast cancer cohort was normal-
ised using U48 and calculated using a vector containing
Podoplanin gene ranging from 101 to 108 copy numbers.
Expression of miRNAs in breast cancer cells was relatively
quantified using the 2nCT method (Pfaffl, 2001).
Cell treatment with miR mimics or inhibitors. All the synthetic
miR inhibitors and mimics were purchased from Sigma–Aldrich
(Irvine, UK). After cancer cells or endothelial cells reached the
logarithmic growth phase, they were transfected with 25 nM of
appropriate miRNA mimics or negative control using Dharmafect
transfection reagents (GE Healthcare, Buckinghamshire, UK)
following the manufacturer’s instruction. Dharmafect 1 reagent
(2 ml ml 1) was used for MCF-7 cells, while Dharmafect 4 reagent
(1 ml ml 1) was used for MDA-MB-231 and endothelial cells.
Electric cell-substrate impedance sensing assay. The electric cell-
substrate impedance sensing (ECIS) Zy instrument and 96W1E
arrays (Applied Biophysics, Inc., Troy, NY, USA) were used for the
measurement of spreading, attachment and migration behaviour of
cancer and endothelial cells. Cells were seeded at a density of
4 104 cells per well and cultured at 371 for 24 h before the electric
impedance of the cell layer was recorded. Each treatment group
was set up with 6 repetitions. After differing time periods, the cell
monolayer in each well was electrically wounded at 2600mA for
20 s and post-wound migration was monitored at multiple
frequencies in the ECIS system.
In-vitro scratch wound assay. Breast cancer cells were seeded into
a 48-well plate at a density of 1 105 cells per well and allowed to
form a monolayer, which was then scratched with a pipette tip
to create a linear wound with a width of around 200 mm wide.
Migration of cells to the wounding gap was monitored by serial
time-lapse imaging using an EVOS FL imaging system (Life
Technologies, Carlsbad, CA, USA) with a  10 objective.
Percentage of wound gap closure was measured using Image J
software (National Institutes of Health, Bethesda, MD, USA; http://
www.rsb.info.nih.gov/ij) and a customised macro.
Cell proliferation. The proliferation level of the cultured cells
with response to various treatments was assessed using the
AlamarBlue assay. Cells were seeded into 96-well plates at a
density of 3000 cells per well and cultured overnight. After
treatment with miR mimics or inhibitors for 48 h, 10 ml of the
AlamarBlue reagent (Serotec, Ltd., Oxford, UK) was added to each
well containing 100 ul of fresh culture medium. Cells were then
incubated for 3 h at 37 1C. The fluorescence was measured with a
fluorescence plate reader (Promega, Southampton, UK) with
excitation at 544 nm and emission at 590 nm. The fluorescence
value was proportional to the numbers of viable cells.
Apoptosis assay. Apoptosis of cells after miR treatment for 24 h
was estimated using Caspase-Glo 3/7 Assay Kit (Promega,
Madison, WI, USA) following the manufacturer’s instruction.
Luciferase activity analysis. The plasmid reporters which con-
tained the predicted 30-UTR sites in Wave-3 for miR-7 were
analysed using a Dual-Glo luciferase assay system according to the
manufacturer’s instructions (Promega). Briefly, plasmids and miR
mimics (miR7 or control) were co-transfected into MCF10A cells
using DharmaFECT Duo transfection reagent (Dharmacon, GE
Healthcare, Hammersmith Imanet, UK). After 48 h, Firefly
luciferase activity was measured using the Promega Dual-Glo
luciferase kit and normalised to Renilla luciferase activity in
GloMax plate reader (Promega).
Flow cytometric analysis. The molecular mechanism by which
miRNA mimics regulate cancer cell behaviour were studied using
flow cytometric analysis of cellular protein molecules. Cells were
collected using HyQtase (Thermo Scientific, St Leon-Rot,
Germany). They were then fixed with 1X fixation solution
(eBioscience, San Diego, CA, USA) and permeabilised with
90–100% methanol. After blocking with 1%BSA solution, they
were then stained with individual primary antibodies (1 : 100) and
fluorescein isothiocyanate (FITC)-conjugated secondary antibodies
(1 : 600. Sigma) sequentially. The primary antibodies were anti-
EGFR (SC-71034, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-IGF1R (SC-712, Santa Cruz Biotechnology), anti-
pMDM2Ser166 (3521, Cell Signaling Technology, Inc., Beverly,
MA, USA) and anti-Wave3 (2806, Cell Signaling Technology),
respectively. Cells were then analysed using a flow cytometer
(CANTO II, BD Biosciences, Oxford, UK).
In-vitro angiogenesis assay. A tubule-formation assay was
performed to evaluate the effect of miRNA mimics on angiogenesis
properties of endothelial cells. Briefly, Matrigel (BD Biosciences), a
basement membrane matrix commonly used to study angiogenesis
in vitro, was placed in a 24-well plate at 200 ml/well. The plate was
then incubated at 37 1C for 1 h to allow Matrigel to solidify.
HMVECs were then plated at a density of 1 105 cells per well in
450 ml of culture medium. Tubule formation of the endothelial cells
Matrigel was monitored using an EVOS FL imaging system (Life
technologies, Paisley, UK) with a  4 objective. Tubule formation
was then measured using Image J software (NIH).
Transwell Matrigel invasion and migration assays. An in vitro
Matrigel invasion assay was used to assess the invasive capability of
breast cancer and endothelial cells respectively. After cancer cells
were transfected with miRNA mimic or negative control for 48 h,
transwell inserts (8-mm pore sise. Greiner Bio-One Stonehouse,
UK) for 24-well plates were pre-coated with 50 ml per insert of
1mgml 1 Matrigel (BD Bioscience), for 1 h at 37 1C. Cells were
seeded into the upper chamber of each insert in 100 ml basal
medium and 650 ml culture medium was added to each lower
chamber. For investigation of tumour-endothelial cell interaction,
tumour cell conditioned medium (TCM) was prepared from MCF-
7 or MDA-MB-231 cells by collecting normal growth medium
from 75 cm flasks of confluent cells. Medium was clarified by
centrifugation.
To understand the transwell invasion (‘homing’) potential of
endothelial cells after pre-treatment with miR-7 mimic with
responding to TCM from breast cancer cells, HMVECs were pre-
treated with 20 nM of mimics of negative control, miR-7 and miR-
140-3p and incubated for 24 h, they were loaded onto the Matrigel-
coated inserts as described above. And in the lower chamber of
each insert, 50% of TCM was mixed with 50% of endothelial cell
growth medium and used as a ‘chemoattractant’. After incubation
at 37 1C for 24 h, HMVECs that penetrated the Matrigel-coated
membrane and adhered to underside of the inserts were dissoci-
ated with cell dissociation solution (MerkMillipore, Watford, UK)
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containing 4 mgml 1 Calcein AM (eBiosciences, Hatfield, UK) for
1 h at 37 1C. The solution containing invaded cells was transferred
to a 96-well black-well plate at a volume of 100 ml per well. Invaded
cells labelled with Calcein AM were then quantified using a
fluorescence plate reader (Promega, Southampton, UK) with
excitation at 490 nm and emission at 520 nm. Migration assay
was performed similarly to the invasion assay described above, but
in the absence of Matrigel.
RT–qPCR. Synthesis of cDNA was performed using 0.5 mg of
RNA and a high-capacity cDNA reverse transcription kit (Thermo
Fisher Scientific) following the manufacturer’s instructions.
Quantitative analysis of the gene transcripts was carried out using
Amplifluor-based technologies, in which a 6-carboxy-fluorescine-
tagged Uniprimer (Biosearch Technologies, Novato, CA, USA) was
used as a probe. A pair of target specific primers were designed and
the anti-sense primer incorporated a Z-sequence (50-ACT-
GAACCTGACCGTACA-30) which was specifically recognised by
the probe (Myakishev et al, 2001). The primer sequences for
the qRT-PCR are listed in Table 2. Real-time quantitative PCR
was carried in an iCycler IQ5 thermocycler (Bio-Rad, Hemel-
Hempstead, UK) using a PrecisionFAST qPCR MasterMixes
(Primerdesign Ltd, Southampton, UK). Cycling conditions were
95 1C for 10min, and 50 cycles of 95 1C for 10 s, 55 1C for 35 s and
72 1C for 10 s. An internal standard was used as control and
GAPDH was used as the housekeeping gene for normalisation.
Statistical analysis. All experimental data were presented as
mean±s.d. unless indicated otherwise. The statistical analysis of
miR expression in human breast cancer specimens was carried out
with Minitab version 14.1 (Minitab Ltd., Coventry, UK) using a
custom written macro and two sample comparison. The statistical
comparisons of other assays were performed using the SPSS
version 20 for Windows (SPSS, Chicago, IL, USA). The significance
of differences in the ECIS data was analysed using the repeated-
measures (RM) ANOVA. One-way analysis of variance (ANOVA)
for other multiple group data. Two group comparison was analysed
using Student’s t-test if data were normally distributed (via
Shapiro-Wilk W test) or Mann–Whitney U-test if data are not
normally distributed. Differences were considered statistically
significant when P-valueso0.05.
RESULTS
Expression of miR-7 is negative associated with the stage, grade
and survival of the breast cancer patients. We evaluated
expression profile of a panel of miRs in a breast cancer cohort
with 10-year follow-up clinical data. As shown in Table 2, the
expression of miR-7 in the breast cancer cohort is negatively
associated with the Nottingham Prognostic Index (NPI)-indicated
prognosis (P¼ 0.028, NPI3 vs NPI1), grade (P¼ 0.0382, Grade 3 vs
Grade 1), and survival (P¼ 0.024, METþDEAD vs SURV1), res-
pectively. We also observed that miR-221-5p expression appeared
to be negatively associated with higher grade (P¼ 0.028, Grade 3 vs
Grade 2), and later stage (P¼ 0.017, TNM3 vs TNM1) although the
sample size of TNM3 was limited (n¼ 7). Likewise, miR-339-5p
expression was also negatively associated with higher grade
(P¼ 0.026, Grade 3 vs Grade 2), and later stage (P¼ 0.043,
TNM2 vs TNM1), respectively. Therefore, these three miRNAs
were considered as lead candidates in the following research.
Differential expression of miRNAs in the breast cancer cells.
Through multiplex miRNA gene expression assays, we found that
there was differential expression of eight miRNAs in a panel of 8
Table 2. Expression of miR-7, miR-221-5p and miR-339-5p in Human Breast Cancer
miR-7 miR-221-5p miR-339-5p
Patients N Mean s.d. s.e. P-value N Mean s.d. s.e. P-value N Mean s.d. s.e. P-value
Normal 15 87.90 141.10 36.40 20 73.30 114.10 25.50 22 73.80 105.20 22.40
Tumour 66 57.89 67.39 8.29 80 56.73 62.08 6.94 80 43.45 49.18 5.50
NPI1 34 69.60 82.70 14.20 38 66.00 78.40 12.70 39 51.20 62.80 10.10
NPI2 18 54.10 56.60 13.30 26 51.57 48.08 9.43 25 38.89 35.57 7.11
NPI3 12 35.68 15.10 4.36 0.028 vs NPI1 14 45.50 29.93 8.00 13 33.79 21.06 5.84
Grade1 11 74.10 93.40 28.10 12 71.50 93.30 26.90 12 56.20 75.40 21.80
Grade2 14 91.30 94.20 25.20 0.0106 vs
Grade3
21 83.40 77.00 16.80 0.028 vs
Grade3
22 63.00 61.00 13.00 0.026 vs
Grade3
Grade3 40 41.66 40.36 6.38 0.0382 vs
Grade1
46 40.59 36.64 5.40 44 30.63 27.53 4.15
TNM1 30 76.40 86.80 15.90 39 72.90 77.90 12.50 39 57.36 62.33 9.98
TNM2 26 47.23 47.06 9.23 28 45.46 43.85 8.29 0.086 vs
TNM3
28 33.20 32.04 6.05 0.043 vs
TNM1
TNM3 6 29.96 4.44 1.81 7 30.54 3.30 1.25 0.0017 vs
TNM1
6 22.38 2.03 0.83 0.0012 vs
TNM1
TNM4 2 29.43 1.21 0.86 2 29.42 1.42 1.01 3 23.65 3.75 2.16 0.0021 vs
TNM1
Alive&Well 48 64.10 77.30 11.20 58 59.75 70.18 9.21 59 45.97 55.57 7.23
With distant metastasis 4 44.03 16.68 8.34 5 39.33 12.25 5.48 5 29.59 10.52 4.71
With local recurrence 3 46.00 20.50 11.90 3 47.70 20.80 12.00 3 35.82 15.99 9.23
Died of breast cancer 8 32.63 12.75 4.51 11 50.30 38.80 11.70 10 37.71 27.90 8.82
With incidence (incl. local
recurrence)
15 38.35 15.55 4.01 0.034 vs
Alive and Well
19 46.99 30.68 7.04 18 35.14 21.94 5.17
With metastasis and death 12 36.43 14.52 4.19 0.024 vs
Alive and well
16 46.85 32.74 8.19 15 35 23.4 6.04
Abbreviations: NPI¼Nottingham Prognostic Index (1: o3.4 (good prognosis); 2: 3.4–5.4 (moderate prognosis); 3: 45.4 (poor prognosis)); TNM¼ tnm classification of malignant tumours.
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breast cancer cell lines with different invasion potential (Figure 1A,
ordered with their invasion potential). MCF-7 (luminal) cells have
the least invasion potential but showed at least a threefold increase
in miR-7 expression compared to all the other breast cancer cells
screened (for example, Po0.0001 MCF-7 vs MDA-MB-231 cells).
miR-339-5p was also expressed strongly in MCF-7 cells compared
to other breast cancer cells (Po0.0001 MCF-7 vs MDA-MB-231
cells). miR-221-5p was only detected in the highly invasive cells
MDA-MB-231 (basal-like), BT-549 and BT-20 cells. miR-186-5p
was expressed at similar levels in all the breast cancer cells, miR-
26a-5p was expressed relatively strongly in MCF-7, ZR-75.1 and
MDA-MB-231 cells compared to the other cells tested. miR-30e-5p
expression level was higher in more invasive MDA-MB-231, BT-
549 and BT-20 cells than the less invasive cells. T-47D did not
show expression of miR-30e-5p and miR-7, but did show high
expression of miR-383-5p and miR-485-5p.
As hypoxia may play a key role in a tumour microenvironment,
we investigated whether it could alter the expression of miRNA in
invasive and non-invasive breast cancer cells (MDA-MB-231 and
MCF-7). We found that hypoxia did not significantly alter miR-7
or miR-221-5p expression in MDA-MB-231 and MCF-7 breast
cancer cells. In contrast, although miR-339-5p expression was
not changed in MDA-MB-231 cells, the high expression in MCF-7
cells was significantly down-regulated (Po0.05 vs normoxia) in
response to hypoxia (Figure 1B).
MDA-MB-231 cells are more sensitive than MCF-7 with
response to the treatment of miR-7 which exerts inhibitory
effect on motility and wound healing potentials. To understand
whether miRNAs can have an effect on invasion of breast cancer
cells, we used the ECIS system to monitor cells behaviour following
transfection of cells with synthetic miRNA mimics. As shown
in Figure 2A, we found that miR-7 inhibited the post-wound
migration of MDA-MB-231 cells after electric wound at 25 h
(Po0.01 vs mimic control) and at 36 h (Po0.01 vs mimic control),
respectively. miR-7 mimic did not show any effect on migration of
MCF-7 after electric wound at 25 h, but began to show inhibitory
effect on migration of MCF-7 cells after electric wound at 36 h
(Po0.05 vs mimic control). In contrast, miR-339-5p mimic did
not show any effect on migration of MDA-MB-231 cells and
MCF-7 cells after wound at the two time points, respectively
(Figure 2B).
The ability of the miR-7 mimic to inhibit the wound healing
potential of cancer cells was confirmed using a manual scratch
assay. As shown in Figure 3A and B, after treatment for 48 h using
miR mimics, both MDA-MB-231 and MCF-7 cells showed reduced
wound healing capacity. However, miR-7 appeared to exert
inhibitory effect earlier on MDA-MB-231 cells than on MCF-7
cells. The scratch assay also confirmed that miR-339-5p had no
effect on wound healing in both MDA-MB-231 and MCF-7 cells in
contrast.
B
Normoxia Hypoxia Normoxia Hypoxia Normoxia Hypoxia
0.12
0.16
0.20 0.40 0.005
0.004
0.003
0.002
0.001
0.000
0.30
0.20
0.10
0.00
0.08
0.04
0.00
miR-7
*
miR-339-5p miR-221-5p
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
M
DA
-2
31
M
CF
-7
M
DA
-2
31
M
CF
-7
M
DA
-2
31
M
CF
-7
0.50
A
0.15
0.10
0.05
0.00
6.00
4.00
2.00
0.00
0.06
0.04
0.02
0.00
0.20
0.15
0.10
0.05
0.00
0.80
0.60
0.40
0.20
0.00
0.0006
0.0004
0.0002
0.0000
0.0015
0.0020
0.0010
0.0005
0.0000
miR-7 miR-339-5p
miR-26a-5p miR-30e-5p miR-383-5p miR-485-5p
miR-221-5p miR-186-5p
0.40
0.30
0.20
0.10
0.00
Invasion
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 e
xp
re
ss
io
n
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
M
DA
-2
31
M
DA
-3
61
BT
-
54
9
M
CF
-7
BT
-
20
BT
-
47
4
T-
47
D
ZR
-7
5.
1
Figure 1. miRNA expression in breast cancer cells and post-wound invasion of breast cancer cells following treatment with miRNA mimics
monitored by the ECIS system. (A) Differential expression of miRNAs in breast cancer cells was quantified using the Megaplex TaqMan MicroRNA
Arrays v2.0 and Megaplex Primer Pools following the manufacturer’s instructions. Small RNA U48 was used to normalise the expression data.
(B) post-wound invasion of breast cancer cells. Cells were transfected in an ECIS plate with miRNA mimics and negative controls (25 nM each),
respectively. The electric wound was performed at 25 h and 36h (2600mA for 20 s). The signal of impedance was continuously recorded in the ECIS
system. *Po0.05. A full colour version of this figure is available at the British Journal of Cancer journal online.
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miR-7 does not have an effect on proliferation and apoptosis in
MDA-MB-231 and MCF-7 cells. We investigated whether the
observed inhibitory effect on cell migration could also have been
attributable to the miRNA effect on cell proliferation or viability
after transfection. 48 h treatment with synthetic miR-7 did not
inhibit proliferation in MDA-MB-231 or MCF-7 cells (Figure 3C
and D, respectively). However, 48 h treatment with the miR-339-5p
mimic showed a small inhibitory effect on proliferation of MDA-
MB-231 cells but not MCF-7 cells.
We further estimated the apoptosis level of breast cancer cells
with response to the treatment of miRNA mimics for 48 h. Caspase
3/7 Glo assay showed that miR-7 and miR-339-5p had no effect on
apoptosis of the breast cancer cells (Figure 3E).
miR-7 regulates expression of IGF-1R, EGFR and WAVE3 in
MDA-MB-231 but not MCF-7 cells. Using online searching tools
including TargetScanHuman 7.0 (http://www.targetscan.org) and
miRBase 21 (http://www.mirbase.org), the predicted binding sites of
miR-7 in potential signalling targets were identified (Figure 4A). As
the targeting of miR-7 to IGFR and IGF1R has been previously
reported (Li and Carthew, 2005; Jiang et al, 2010), we therefore only
performed the validation of the predicted target sites in Wave3 for
miR-7 using the luciferase assay. As shown in Figure 4B, in the
presence of the luciferase plasmid containing the target site at Position
396 in Wave3, The luciferase signal was reduced significantly with the
response to miR-7 mimic (Po0.05, vs control). In the presence of the
luciferase plasmid containing the target site at Position 2178 in
Wave3, although it appeared that the luciferase signal was reduced
with the response to miR-7 mimic, there was no significance.
FACS analysis showed that the tyrosine kinase receptors EGFR,
IGF1-R and WAVE 3 (downstream effector of actin
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polymerisation) were expressed in both MDA-MB-231 and MCF-7
cells. 48 h treatment of these breast cancer cells with 25 nM miR-7
mimic compared to a mimic control caused the down-regulation of
EGFR (30%, Figure 4C), IGF-1R (32%, Figure 4E) and WAVE-3
(12%, Figure 4G) in MDA-MB-231 cells, but had no effect on these
proteins in MCF-7 cells (Figure 4D, F and H).
We further evaluated the endogenous gene expression of IGF-1,
EGFR and WAVE3 in the two cell lines by real-time qPCR. The
gene expression of miR-7 targets, EGFR and WAVE3, were
significantly higher in MDA-MB-231 cells compared to MCF-7
cells (Po0.05, respectively). This may partially explain why miR-7
mimic was more potent in MDA-MB-231. However, we cannot
exclude other possible mechanisms, as in our gene expression
data, the gene expression level of IGF-1R was the same in two cell
lines, and also ERK, STAT3, mTOR genes were all overexpressed in
MDA-MB-231 cells compared to MCF-7 cells (Supplementary
Figure 1).
miR-7 mimic inhibits post-wound migration, proliferation and
tubule formation of HMVEC endothelial cells. We used the
ECIS system to investigate whether miR-7 had an effect on the
migration capacity of human endothelial cells which plays the key
role in tumour angiogenesis. Confluent monolayers of HMVEC
cells were transfected with miRNA mimic or appropriate control
for 48 h prior to the creation of an electric wound. As shown in
Figure 5A, miR-7 and miR-140-3p mimics significantly inhibited
the post-wound migration (RM ANOVA Po0.0001 vs mimic
control, respectively). However, the mimics of miR-339-5p, miR-
339-3p and miR-140-3p did not show any effect on HMVEC
migration.
We further evaluated the effect of miR mimics on the prolifera-
tion of HMVECs using the AlamarBlue cell proliferation assay. As
shown in Figure 5B, 48 h treatment with miR-7 inhibited the
proliferation of HMVECs by approximately 12% (Po0.05 vs
mimic control). Other miR mimics examined including miR-339-
5p, miR-339-3p, miR-140-5p, miR-140-3p did not show any effect
on proliferation.
As tubule formation on Matrigel can indicate the angiogenic
capacity of endothelial cells in vitro, we performed this assay on
HMVECs following 48 h treatment with miR mimics. HMVEC
control cells formed large tubules on Matrigel after 18 h. As shown
in Figure 5C, miR-7 significantly inhibited the tubule formation of
HMVECs on Matrigel by approximately 83% (Po0.0001 vs mimic
control). Tubule formation of HMVECs was also inhibited by
other miR mimics including miR-339-5p (B36%, Po0.001), miR-
140-5p (B21%, Po0.05) and miR-140-3p (B32%, Po0.01) at
different levels. miR-339-3p did not show any effect on HMVEC
tubule formation.
Endothelial cell migratory and invasive behaviours in response
to TCM from breast cancer cells can be inhibited by the miR7
mimic. We further investigated the indirect tumour-endothelium
interaction using the transwell insert system. As shown in
Figure 5D, HMVECs did not show difference of transwell invasion
through Matrigel with response to basal control medium, TCM
from MDA-MB-231 and TCM from MCF-7, respectively. How-
ever, HMVECs treated with miR-7 mimic showed a decreased level
of transwell invasion with response to basal control medium
(Po0.01), TCM from MDA-MB-231 (Po0.0001) and TCM from
MCF-7 (Po0.0001), respectively. Interestingly, miR-7 showed an
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additional inhibitory effect of HMVEC invasion in the presence
of TCM from MDA-MB-231 (Po0.05 vs control medium) and
MCF-7 cells (Po0.05 vs control medium), respectively. In contrast,
we investigated the miR-140-3p mimic for its effect on invasion
of HMVECs, and found no significance, which was independent of
the medium used as chemo attractant.
In a parallel experimental manner, we investigated the transwell
migration of HMVECs after miRNA treatment. As shown in
Figure 5E, after the treatment with miRNA mimic, we did not find
any change in the migration of HMVEC s with response to TCM
from MDA-MB-231 and MCF-7 cells. On the contrary, miR-7
decreased the migration capacity of HMVECs with response to
basal medium (Po0.01 vs mimic control) and TCM from MDA-
MB-231 cells (Po0.05 vs mimic control), respectively. In the
presence of TCM from MCF-7 cells, no inhibitory effect of miR-7
on HMVEC migration was observed. Again, miR-140-3p mimic
did not show significant effect on transwell migration of HMVECs
independently of the medium used as chemo attractant.
miR-7 modulates transcription of CXCR4 and CXCR7 in
HUVEC cells. As the angiogenic potential of endothelial cells is
regulated by a variety of angiogenic-associated molecules, we used
qPCR to analyse the gene expression profile of those molecules in
HMVEC cells with response to the treatments of miR mimics. As
shown in Figure 6A, basal HMVEC cells expressed genes including
the chemokine receptors CXCR4 and CXCR7, VEGFR, angiopoie-
tin-2 (ANGPT2), thrombospondin-1 (THBS1) and the chemokine
GRO alpha (CXCL1). Interestingly, the qPCR data indicated that
miR-7 downregulated expression of the CXCR4 gene (Po0.01 vs
mimic control) but upregulated expression of CXCR7 (Po0.01 vs
mimic control). Treatment with miR-339-3p or miR-339-5p did
not significantly affect expression of any of the genes investigated.
DISCUSSION
Breast cancer is a heterogeneous disease and the development of
personalised treatments in the future will depend on the
identification of prognostic and predictive gene expression
signatures which may complement traditional clinic-pathological
parameters (Reis-Filho and Pusztai, 2011). Non-coding miRNAs
are a large group of molecules with over 1400 human miRNAs
currently identified. Our study focussed on the differential
expression of miRNAs in breast cancer types and aimed to
identify a link between specific miRNAs and the invasiveness or
metastatic potential of the tumour cells. Gene expression assays
showed that miR-7 and miR-339-5p had high expression in MCF-7
cells, but very low expression in MDA-MB-231 cells. Our cohort
data also showed that miR-7 is negatively associated with
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prognosis, grade, survival and metastasis of breast cancer patients,
whereas miR-339-5p is negatively associated with grade and stage
of the patients. This pattern of miR-7 expression has similarly been
reported in a breast cancer cell line miRNA expression profiling
study (Riaz et al, 2013). This large study showed that the miRNA
transcriptome is complex, but can be broadly sub-divided into
miRNAs expressed in luminal-type hormone receptor positive cells
and ER negative, often triple negative, epithelial-mesenchymal
transition type (EMT) cells in typically more aggressive tumours.
As miRNA expression predominantly mirrors ER expression, it has
been suggested that a significant number of miRNAs are under
control of ER regulation and in MCF-7 cells, miR-7 has been
identified as an important miRNA significantly induced by
oestradiol, the most potent oestrogenic hormone (Masuda et al,
2012). Since miR-7 and miR-339-5p seem to be expressed at higher
levels in the non-invasive MCF-7 cells, this suggests that high levels
of these miRNAs may play a role in inhibiting invasion. In breast
cancer cells, miR-7 has been shown to inhibit the expression of
Pak-1, an invasion promoting kinase and transfection with miR-7
was found to decrease invasion in MDA-MB-231 cells (Reddy et al,
2008). However, the role of miR-7 is likely to be more complex, as
other reports describing detailed analysis in primary ER positive
breast cancers have shown that high expression of four miRNAs,
including miR-7, were in contrast, linked to early relapse and
reduced time to distant metastasis (Foekens et al, 2008). Hypoxia
is the consequence of an aggressive tumour microenvironment
and a functional link has previously been demonstrated between
hypoxia and micro RNA expression, with a defined group of
miRNAs showing increased expression in response to low oxygen
(Kulkarni et al, 2012). Despite this, we did not observe any effect of
hypoxia on the expression of miR-7 or miR-339-5p in MDA-MB-
231 cells.
Our finding of increased miR-339-5p in MCF-7 cells has
similarly been reported in a study where it was shown to be
expressed 5-10 fold higher in these poorly invasive cells compared
to highly invasive MDA-MB-231 and MDA-MB-468 cells, where
increased miR-339-5p inhibited cell migration (Wu et al, 2010).
miR-339-5p has been shown to be down-regulated in several
cancers, including breast cancer, lung cancer and hepatocellular
carcinoma and its expression level may be used as a biomarker to
predict lymph node metastasis and prognosis in cancers (Rani et al,
2013; Wang et al, 2014, 2015). Our results have also shown that
miR-339-5p expression could be reduced in MCF-7 cells grown
under hypoxic stress as may be expected in an aggressive tumour
environment.
Expression of miR-221-5p appeared to be expressed more
strongly in ER negative cells but is also correlated strongly with
invasive potential, with the most invasive ER negative cell lines,
MDA-MB-231 and BT-549 expressing the highest levels in our
study. This result fits in reassuringly with previous findings that
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miR-221 is negatively regulated by ERa, hence the low expression
we found in ER positive cells. Increased expression of miR-221
has been shown to induce genes involved in invasion and survival,
generating a more metastatic tumour-type. It has even been
suggested that the direct interaction of miR-221 with ER can cause
a phenotypic shift of ER-positive cells to ER-negative more
aggressive cells (Di Leva et al, 2010; Riaz et al, 2013). Analysis of
breast cancer tissue has also confirmed that high miRNA-221
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expression correlates with advanced clinical stage and poor
prognosis, suggesting its possible role as a biomarker for predicting
patient survival (Eissa et al, 2015). Our results suggest that
expression of miR-7, miR-339-5p and miR-221-5p may represent
a powerful diagnostic tool for predicting metastasis in breast cancer
patients.
Like miR-221, miR-30e-5p was also found in our study to be
upregulated in MDA-MB-231 cells compared to MCF-7, however
these results do not closely mirror reported findings in tissue
samples. In contrast, in breast cancer tissue, downregulation of
miR-30e has been defined as ‘risk-associated’ and shown to
correlate with worse patient outcome (Gasparini et al, 2014).
Increased miR-30e-5p expression has therefore been associated
with good prognosis and considered as a protective prognostic
factor in lymph node-negative breast cancer patients with ERþ /
ERBB2 tumours (D’Aiuto et al, 2015) and its expression level is
believed to be useful as a powerful diagnostic tool (Gasparini et al,
2014).
Our study enabled us to compare the functional effect of
increased miR-7 or miR-339-5p expression in an invasive triple
negative (ER , PR and HER ) MDA-MB-231 and a non-
invasive double positive (ERþ , PRþ and HER ) MCF-7 cell line.
Cell migration was measured in a label-free, real-time fashion
using the ECIS system and with a wound-healing (scratch) assay to
evaluate the overall physical gap-closure properties of cancer cells.
Increasing the miR-7 level by transfection with synthetic miR-7
mimic caused a significant decrease in MDA-MB-231 migration
measured by both ECIS and scratch assays, whereas an increase in
miR-339-5p had no effect. Post-wound migration in MCF-7 cells,
as measured by ECIS, was not changed by addition of extra miR-7
mimic at an earlier period. The inhibition detected in MCF-7 cells
in the scratch assay can be observed later than that in MDA-MB-
231 cells. This confirms that miR-7 expression can play a role in
inhibiting breast cancer invasive capability and acting as a tumour
suppressor as has been previously described (Reddy et al, 2008),
but also suggests that miR-339-5p does not have the same effect in
our MDA-MD-231 cells. We propose that invasive breast cancers
may be more sensitive than less aggressive cells to treatment by
miR-7 mimic as a micro RNA-based anti-tumour therapy.
Bioinformatic approaches were used to find signalling proteins
with potential binding targets for miR-7, enabling EGFR, IGF-1R
and WAVE3 to be identified. Both human EGFR and IGF-1R
mRNA 30-untranslated regions contain three miR-7 target sites.
We observed that transfection with mimic miR-7 suppressed
expression of EGFR, IGF-1R and WAVE3 in MDA-MB-231 cells
but did not change expression of these proteins in MCF-7 cells.
The tyrosine kinase receptors, EGFR and IGF-1R are oncogenes
frequently observed to be mutated or amplified in a wide range
of solid tumours and have been considered as an important
therapeutic target for clinical studies partly because of their
involvement in human cancer progression and metastasis (van der
Noll et al, 2015). In cancers including breast, lung, colorectal and
glioblastoma it has been reported that miR-7 inhibits EGFR and its
downstream signalling pathways [31–33]. These include raf1-erk1/
2, crucial for proliferation, and PI3K/AKT and PAK1 pathways
that both play a crucial role in cancer cell migration and invasion
(Liu et al, 2014; Zhou et al, 2014; Suto et al, 2015). Interestingly,
our data suggest that miR-7 is more likely to regulate mechanisms
controlling migration and invasion instead of proliferation and
apoptosis in aggressive breast cancer cells. In ovarian and gastric
cancer studies, overexpression of miR-7 has been shown to inhibit
metastasis and to reverse epithelial-mesenchymal transition (EMT)
caused by EGFR and IGF1-R downregulation (Zhou et al, 2014). In
addition to directly inhibiting EGFR expression, reports have also
demonstrated that miR-7 transfection can independently inhibit
downstream signalling pathways including PAK1 expression by
targeting the 30-untranslated region of Pak1 mRNA (Reddy et al,
2008) and AKT through targeting upstream regulators (Kefas et al,
2008). WAVE3 is part of a family of scaffold proteins that can link
upstream receptor tyrosine kinase signals to the activation of the
ARP2/3 complex, leading to a burst of actin polymerisation. This is
crucial for the reorganisation of the cytoskeleton in cell movement
and hence plays a role in cancer cell invasion (Takenawa and
Suetsugu, 2007). It interacts with the PI3kinase pathway and acts as
a pro-metastatic molecule in breast cancer (Sossey-Alaoui et al,
2005; Kulkarni et al, 2012; Taylor et al, 2013) since knock-down of
WAVE3 results in decreased cell invasion and metastasis (Sossey-
Alaoui et al, 2007). Our results have shown for the first time that
WAVE3 is another downstream signalling protein involved in cell
migration that appears to be directly targeted by miR-7.
Expression of WAVE3, IGF-1R and EGFR were all significantly
inhibited by the addition of mimic miR-7 to MDA-MB-231,
while it had no effect on the levels of these proteins expressed in
MCF-7 cells. One explanation for the difference in sensitivity to
miR-7 may be that MCF-7 cells express high levels of miR-7
possibly via ER signalling (Masuda et al, 2012) and have developed
compensatory mechanisms that enable the cells to maintain
WAVE3, IGF-1R and EGFR protein levels. The ability of miR-7
to reduce the migratory capability in MDA-MB-231 cells but not
MCF-7 cells may also be partly explained by the fact that miR-7
only reduces the level of these proteins, which have a role in cell
migration, in MDA-MB-231 cells.
Tumour-associated angiogenesis is a critical step during the
metastatic process, we therefore investigated whether microRNAs
could also be used as anti-angiogenic strategies to control tumour
spread. We found that adding mimic miR-7 significantly inhibited
the ability of the HMVECs to migrate, proliferate and reduced
tubule formation by B80%, suggesting this microRNA may be
used to inhibit angiogenesis. In vivo models have previously
identified miR-7 as a potent negative regulator of angiogenesis
producing effects similar to the anti-angiogenic drug sunitinib
(Babae et al, 2014). Our results also showed that although having
no effect on proliferation, miR-140-30p was another microRNA
with anti-angiogenesis potential as it also demonstrated significant
inhibition of HMVEC migration and tubule forming ability. Pre-
treatment of HMVECs with miR-7 reduced the ability of the cells
to migrate and invade in response to signals from breast cancer
cells. Importantly, these results imply that in addition to inhibiting
angiogenic potential, miR-7 may be an inhibitor of the homing and
migration of endothelial cells in response to factors released by
aggressive breast tumours. Results showed that expression of a
selection of pro or anti-angiogenic factors (ANGPT-2, GROa
(CXCL1), TSP-1) normally secreted by endothelial cells did not
appear to be directly regulated by treatment with miR-7. However,
treatment of endothelial cells with miR-7 significantly regulates
expression of the chemokine receptors CXCR4 and CXCR7. Both
of these transmembrane G-protein coupled proteins are receptors
for the chemokine ligand CXCL12 (SDF-1a) which triggers
signalling via PI3kinase/Akt and erk1/2 to induce chemotaxis
(Wu¨rth et al, 2014). CXCR4/CXCL12 axis is recognised to play an
important role in breast cancer metastasis and angiogenesis, as
CXCL12 is produced by stromal cells and is expressed at high levels
in the main sites of breast cancer metastasis (lymph nodes, bone
marrow, liver and lung; Mu¨ller et al, 2001). Chemokine receptors
are widely expressed on hematopoietic and endothelial cells, but
CXCR4 is also known to be overexpressed on breast cancer cells, a
factor that has been correlated with metastasis and poor patient
survival (Mu¨ller et al, 2001; Zhang et al, 2014). CXCR4 has a
predicted binding site for miR-7 in the 3’untranslated region,
therefore the downregulation of this protein in endothelial cells by
the addition of miR-7 may be considered to be one of the
mechanisms that decreased the HMVEC ability to migrate in
response to chemoattractants produced by breast cancer cells. The
upregulation of CXCR7 by miR-7 did not prevent the reduced
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chemotaxis in HUVEC cells caused by miR-7, indeed it may be
postulated that since CXCR7 has been reported to have a function
in scavenging CXCL12 and activating b-arrestin to internalise
CXCR4, upregulation by miR-7 may have augmented the
reduction in CXCR4 signalling (Wu¨rth et al, 2014). A number of
microRNAs have previously been shown to target CXCR4 and to
supress migration in cancer cells including nasopharangeal
carcinoma (Lu et al, 2014), colon cancer (Li et al, 2013) and
breast cancer (Liang et al, 2007). miR-126 has also been shown to
up and down-regulate CXCR4 and CXCL12 in HUVECs
(Mondadori dos Santos et al, 2015). To the best of our knowledge
this is the first report to show that miR-7 can downregulate
CXCR4 and inhibit endothelial cell chemotactic response to breast
cancer cells.
In conclusion, we identify that miR-7 is expressed at a low level
in highly invasive cells, and when added as a form of mimic,
it appears to play a more potent role in inhibition of invasive
breast cancer cell migration. More importantly, miR-7 mimic
indeed has a dual effect as it also significantly inhibits the
proliferative, chemotactic and angiogenic-like homing character-
istics of endothelial cells especially in response to chemoattractant
factors produced by aggressive breast cancer cells. As illustrated in
Figure 6B, our findings in this study suggests that miR-7 may be
developed as an anti-cancer therapeutic potentially capable of
supressing breast cancer metastasis and tumour-associated angio-
genesis simultaneously.
CONCLUSIONS
This is the first report demonstrating that the highly metastatic
MDA-MB-231 cells are more sensitive to the inhibitory effect of
miR-7 mimic treatment than the poorly invasive MCF-7 cells. This
distinguishable response may be due to the downregulation of
EGFR, IGF1R and Wave3 in breast cancer cells. miR-7 also inhibits
the proliferation, migration and invasion of endothelial cells.
More importantly, miR-7 suppresses the homing and migration
of endothelial cells to more aggressive tumour cell conditions,
suggesting its dual-inhibitory role in tumour microenvironment
and potential therapeutic value.
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